Onychomatricoma
| Onychomatricoma | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | Dermatology |
| Symptoms | Thickened nail, nail plate discoloration, splinter hemorrhages |
| Complications | |
| Onset | |
| Duration | |
| Types | N/A |
| Causes | Unknown |
| Risks | |
| Diagnosis | Clinical examination, dermoscopy, histopathology |
| Differential diagnosis | Onychomycosis, glomus tumor, subungual exostosis |
| Prevention | N/A |
| Treatment | Surgical excision |
| Medication | |
| Prognosis | Excellent with complete excision |
| Frequency | Rare |
| Deaths | N/A |
Onychomatricoma is a rare benign tumor of the nail matrix that was first described in 1992 by Baran and Kint. It is characterized by a slow-growing, painless, thickened nail plate with splinter hemorrhages and xanthonychia. The tumor is often misdiagnosed due to its rarity and lack of awareness among clinicians.
Clinical Presentation[edit]
Patients with onychomatricoma typically present with a slow-growing, thickened nail plate that may be associated with pain. The nail plate often shows longitudinal ridging and splitting, with splinter hemorrhages and xanthonychia. The nail may also be deformed or partially destroyed.
Diagnosis[edit]
The diagnosis of onychomatricoma is often challenging due to its rarity and the lack of specific clinical features. The diagnosis is usually confirmed by histopathology following a nail biopsy. Histologically, the tumor is characterized by the presence of fibroepithelial papillae and a thickened nail matrix.
Treatment[edit]
The treatment of choice for onychomatricoma is complete surgical excision of the tumor. This usually results in a cure, although recurrence has been reported in some cases.
Prognosis[edit]
The prognosis for patients with onychomatricoma is generally good, as the tumor is benign and does not metastasize. However, the tumor can cause significant morbidity due to its effects on the nail and the potential for recurrence.
See Also[edit]
References[edit]
- Baran R, Kint A. Onychomatricoma. J Am Acad Dermatol. 1992;26(2 Pt 1):247-250.
- Perrin C, Baran R, Pisani A, et al. The onychomatricoma: additional histologic criteria and immunohistochemical study. Am J Dermatopathol. 2002;24(3):199-203.
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


